The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis
Abstract
Omega-3 fatty acid supplements containing both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to reduce triglycerides but also increase low-density lipoprotein (LDL). Whether EPA or DHA given as monotherapy has differential effects on serum lipoproteins has not been systematically evaluated. We performed a meta-analysis of randomized placebo-controlled trials of monotherapy with EPA (n=10), DHA (n=17), or EPA versus DHA (n=6). Compared with placebo, DHA raised LDL 7.23 mg/dL (95% CI, 3.98–10.5) whereas EPA non-significantly reduced LDL. In direct comparison studies, DHA raised LDL 4.63 mg/dL (95% CI, 2.15–7.10) more than EPA. Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies. DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not. Although EPA and DHA both reduce triglycerides, they have divergent effects on LDL and high-density lipoprotein. Further research is needed to elucidate the mechanisms and significance of these differences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apparently independently of formulation, some omega-3 dietary supplements contain cholesterol, oxidized fatty acids, saturated fatty acids, or other contaminants that can affect their net risk-benefit relationship.57,105”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [57]
In the citing paper
“Previous systematic reviews and meta‐analyses have been unable to reveal a significant dose–response relationship. 12 , 14”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [14]
In the citing paper
“These dose predictions cannot be performed in previous meta‐analyses that failed to reveal a significant dose–response relationship 12 , 14 and brought uncertainty. 6 , 9 , 13 , 15”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [14]
In the citing paper
“The lack of effects on ALT, HDL, and LDL may reflect the selective action of omega-3 fatty acids. Their lipid-lowering effects primarily target the triglyceride metabolic pathway, including promoting fatty acid oxidation and reducing lipogenesis by activating PPAR-α and inhibiting SREBP-1c,42,43 while exerting weaker direct effects on cholesterol reverse transport and synthesis.44,45”
In the citing paper
“While both EPA and DHA reduce triglycerides (TG), DHA may raise low-density lipoprotein cholesterol (LDL-C) [5, 6].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Homogeneity across studies was assessed using the methods of DerSimonian and Laird [17] to determine the appropriateness of combining mean differences from individual studies.”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707 · cited 1×
“Omega-3 polyunsaturated fatty acids administered as fish oil supplements or prescription omega-3 ethyl esters lower plasma triglyceride concentrations [5–7].”
BackgroundKliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 2×
“EPA and DHA have been shown to reduce hepatic synthesis of triglycerides, increase hepatic fatty acid beta-oxidation, and promote myocardial fatty acid uptake and metabolism by acting as endogenous ligands for peroxisome proliferator–activated receptor (PPAR)-α and PPAR-γ [9–11].”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329 · cited 1×
“Hypertriglyceridemia is associated with increased cardiovascular disease risk in numerous prospective and randomized clinical trials [1–3].”
Backgroundn-3 fatty acids and serum lipoproteins: human studies
Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169 · cited 1×
“EPA and DHA have been shown to reduce hepatic synthesis of triglycerides, increase hepatic fatty acid beta-oxidation, and promote myocardial fatty acid uptake and metabolism by acting as endogenous ligands for peroxisome proliferator–activated receptor (PPAR)-α and PPAR-γ [9–11].”
BackgroundMori, T. A., Burke, V., Puddey, I. B., Watts, G. F., O’Neal, D. N., Best, J. D., & Beilin, L. J. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1085 · Cited by 588 · cited 4×
“[32] (2000) N=56 men EPA: 4 N=19 EPA: 165 (32.”
BackgroundInfluentialOmega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives
Harris, W. S., Miller, M., Tighe, A. P., Davidson, M. H., & Schaefer, E. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.008 · Cited by 552 · cited 1×
“EPA and DHA have been shown to reduce hepatic synthesis of triglycerides, increase hepatic fatty acid beta-oxidation, and promote myocardial fatty acid uptake and metabolism by acting as endogenous ligands for peroxisome proliferator–activated receptor (PPAR)-α and PPAR-γ [9–11].”
Background
Research works printed but not linked: 1
- •• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels: the MARINE trial. Am J Card. 2011;In press. This large placebo-controlled trial of EPA demonstrates a reduction in triglycerides without raising LDL in participants with very high triglyceride levels.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“326 The efficacy of omega-3 fatty acids in lowering serum TGs has also been reported in meta-analyses.(157) Recently, the EpanoVa fOr Lowering Very high triglyceridEs II (EVOLVE II) trial confirmed the efficacy of omega-3 fatty acids in lowering serum TGs.”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“– 283 The efficacy of omega-3 fatty acids to lower serum TGs has also been reported in meta-analyses.(284) One meta-analysis included 63 030 subjects from 20 trials and reported no overall effect of omega-3 fatty acids on composite CV events {relative risk [RR] 0.”
BackgroundNational Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“Wei et al.173 conducted a meta-analysis to evaluate and compare the effects of EPA and DHA on lipoprotein lipids.”
MethodSelf-citation
Metadata
- Authors
- Wei, M. Y., & Jacobson, T. A.
- Affiliations
- Emory University (US)
- Corresponding author
- Wei, Melissa Y.
- Jacobson, Terry A.
- Venue
- Current Atherosclerosis Reports
- Published
- 2011-10-06
- Volume
- 13
- Issue
- 6
- Pages
- 474-483
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W2138013532
- Cited by
- 284
- References
- 44
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 17 · 2022: 13 · 2021: 17 · 2020: 20 · 2019: 27 · 2018: 16 · 2017: 30 · 2016: 30 · 2015: 27 · 2014: 30 · 2013: 20 · 2012: 12
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- eicosapentaenoic acid, docosahexaenoic acid, omega-3 fatty acids, serum lipids, LDL cholesterol, triglycerides, HDL cholesterol, monotherapy, hypolipidemic effect
- MeSH terms
- Docosahexaenoic Acids, Humans, Lipids, Eicosapentaenoic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1007/s11883-011-0210-3
- The paper
- Wei, M. Y., & Jacobson, T. A. (2011). Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-011-0210-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.